

From the INTERNATIONAL SEARCHING AUTHORITY

To:

BAYER AKTIENGESELLSCHAFT D-51368 Leverkusen

GERMANY

Bayer AG
Bayer Business Services
Law and Patents

19. Nov. 2003

EINGANG

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

/ 300/01 Corp. Wort Staven,

Date of mailing

(day/month/year)

10/11/2003

Applicant's or agent's file reference

RCK30-WO

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/EP 03/06168

International filing date (day/month/year)

12/06/2003

Applicant

BAYER AKTIENGESELLSCHAFT

1. 🛚	Filing of	amendments a	otified that the International Search Report has been established and is transmitted herewith. Ind statement under Article 19: If he so wishes, to amend the claims of the International Application (see Rule 46):
	When?		or filing such amendments is normally 2 months from the date of transmittal of the earch Report; however, for more details, see the notes on the accompanying sheet.
	Where?	Directly to the	International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14.35
	For more	e detailed instru	uctions, see the notes on the accompanying sheet.
2.			notified that no International Search Report will be established and that the declaration under ect is transmitted herewith.
3.	the	protest together	est against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: with the decision thereon has been transmitted to the International Bureau together with the to forward the texts of both the protest and the decision thereon to the designated Offices.

4. Further action(s): The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016

Authorized officer

30

John De Bruijn

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international phulication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	(Form	otification of Transmittal of International Search Report PCT/ISA/220) as well as, where applicable, item 5 below.	_
RCK30-WO	ACTION	·	
International application No.	International filing date (day/mont	th/year) (Earliest) Priority Date (day/month/year)	
PCT/EP 03/06168	12/06/2003	13/06/2002	
Applicant			
BAYER AKTIENGESELLSCHAFT			
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Sea ansmitted to the International Burea	arching Authority and is transmitted to the applicant u.	
This International Search Report consists X It is also accompanied by	of a total of 6 sh a copy of each prior art document of	eets. cited in this report.	
Basis of the report			
With regard to the language, the language in which it was filed, unl	international search was carried ou ess otherwise indicated under this i	t on the basis of the international application in the tem.	
the international search w Authority (Rule 23.1(b)).	ras carried out on the basis of a tran	nslation of the international application furnished to this	
was carried out on the basis of the	d/or amino acid sequence disclose sequence listing: onal application in written form.	ed in the international application, the international search	
filed together with the inte	rnational application in computer re	adable form.	
furnished subsequently to	this Authority in written form.	·	
furnished subsequently to	this Authority in computer readble	form.	
the statement that the sub international application a	osequently furnished written sequents is filed has been furnished.	nce listing does not go beyond the disclosure in the	
the statement that the info furnished	ormation recorded in computer read	able form is identical to the written sequence listing has be	een
2. X Certain claims were fou	nd unsearchable (See Box I).		
3. Unity of invention is lac	king (see Box II).		
4. With regard to the title,			
the text is approved as su	ibmitted by the applicant		
	thed by this Authority to read as follo	ows:	
	,		
		•	
5 Wish remark to the chief			
5. With regard to the abstract, X the text is approved as su	shmitted by the applicant		
the text has been establis	hed, according to Rule 38.2(b), by t	this Authority as it appears in Box III. The applicant may, I search report, submit comments to this Authority.	
6. The figure of the drawings to be pub			
as suggested by the appli		None of the figures.	
because the applicant fail	ed to suggest a figure.		
because this figure better	characterizes the invention.		



A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C235/34 A61K31/197 A61P13/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C A61K


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


BEILSTEIN Data, WPI Data, EPO-Internal, PAJ, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X /	WO 01 68591 A (HOFFMANN LA ROCHE) 20 September 2001 (2001-09-20) page 2, line 3 -page 3, line 10 examples 1,2,6,7,13-15	1-18
x /	AMINO, Y ET AL: "Phenylalanine derivatives enhancing intestinal absorption of insulin in mice" CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 36, no. 11, 1988, pages 4426-4434, XP002257551 PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP ISSN: 0009-2363 examples 12,26,29,13,32,33,34; table II	1-3,8-15
	-/	

X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
15 October 2003	10/11/2003
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	O'Sullivan, P



C.(Continua	tion) DOCUMENTS CONSIDÉRED TO BE RELEVANT		3/06168
	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
x/	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am		1
	Main, DE; Database accession no. 4754437 XP002257552 abstract & MOHAN, R ET AL: JOURNAL OF MEDICINAL		
	CHEMISTRY., vol. 34, no. 8, 1991, pages 2402-2410, AMERICAN CHEMICAL SOCIETY., US ISSN: 0022-2623		
x /	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 8632878		1,3
	XP002257553 abstract & SCHLIZER, M ET AL: BIOORGANIC & MEDICINAL CHEMISTRY., vol. 8, no. 8, 2000, pages 1991-2006, ELSEVIER SCIENCE LTD., GB		
x 🗸 📗	ISSN: 0968-0896 DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am		1
	Main, DE; Database accession no. 8630331 XP002257554 abstract & SCHLIZER, M ET AL: BIOORGANIC & MEDICINAL CHEMISTRY., vol. 8, no. 8, 2000, pages 1991-2006, ELSEVIER SCIENCE LTD., GB		-
x 🖊	ISSN: 0968-0896 DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am		1
	Main, DE; Database accession no. 7921133 XP002257555 abstract & KMETIC, M ET AL: JOURNAL OF HETEROCYCLIC		
	CHEMISTRY., vol. 34, no. 6, 1997, pages 1705-1708, HETERO CORP., TAMPA, FL., US ISSN: 0022-152X		
	-/	•	



A Category* Combined document, with indication-where appropriate, of the relevant passages Relevant to claim No. DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6432016 XP002257556 abstract & BLUME, HET AL: ARZNEIMITTEL FORSCHUNG / DRUG RESEARCH., vol. 31, no. 10, 1981, pages 1731-1735, VERLAG FUER NATURNISSENSCHAFTEN GMBH, AULENDORF, DE ISSN: 0004-4172 X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6330994 XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579-582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091-150X X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY, LONDON, GB ISSN: 0368-1769 X US 4 670 584 A (FUKUSHIMA KOJI ET AL) 2 June 1987 (1987-06-02) examples S-27; table 2 MO 00 50397 A (TAKAHASHI AKIHIRO; KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, 1ine 13 -page 15, 1ine 8 table 3 claim 1 A US 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22) claim 1	C/Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6432016 XP002257556 abstract & BLUME, H ET AL: ARZNEIMITTEL FORSCHUNG / DRUG RESEARCH., vol. 31, no. 10, 1981, pages 1731-1735, VERLAG FUER NATURWISSENSCHAFTEN GMBH, AULENDORF., DE ISSN: 0004-4172 X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6330994 XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579-582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091-150X X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY, 1960, pages 3457-3461, CHEMICAL SOCIETY, 1960, pages 3457-3461, CHEMICAL SOCIETY, 1960, pages 3457-3461, CHEMICAL SOCIETY, 1970, Pages 3457-3461, CHEMICAL SOCIETY, 1987-06-02) examples 5-27; table 2 MO 00 50397 A (TAKAHASHI AKIHIRO; KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3 claim 1 A W 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22)			Relevant to claim No.
Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6432016 XP002257556 abstract & BLUME, H ET AL: ARZNEIMITTEL FORSCHUNG / DRUG RESEARCH., vol. 31, no. 10, 1981, pages 1731–1735, VERLAG FUER NATURWISSENSCHAFTEN GMBH, AULENDORF, DE ISSN: 0004–4172 X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6330994 XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579–582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091–150X X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY, 1960, pages 3457–3461, CHEMICAL SOCIETY, 1970, pages 3457–3461, CHEMICAL SOCIETY, 1987–06-02) examples 5–27; table 2 MO 00 50397 A (TAKAHASHI AKIHIRO; KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000–08–31) page 14, line 13 –page 15, line 8 table 3 claim 1 A US 4 7714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987–12-22)			
Database accession no. 6432016 XP002257556 abstract 8 BLUME, H ET AL: ARZNEIMITTEL FORSCHUNG / DRUG RESEARCH., vol. 31, no. 10, 1981, pages 1731-1735, VERLAG FUER NATURWISSENSCHAFTEN GMBH, AULENDORF., DE ISSN: 0004-4172 DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6330994 XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579-582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091-150X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY, 1960, pages 3457-3461, CHEMICAL SOCIETY, 1960, pages 3457-3461, CHEMICAL SOCIETY, LONDON, GB ISSN: 0368-1769 X US 4 670 584 A (FUKUSHIMA KOJI ET AL) 2 June 1987 (1987-06-02) examples S-27; table 2 WO 00 50397 A (TAKAHASHI AKIHIRO; KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14; line 13 -page 15, line 8 table 3 claim 1 A US 4 714 713 A (FUKUSHIMA KOJI ET AL) 2 December 1987 (1987-12-22)	X ✓ .	Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am	1,4
Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 6330994 XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579–582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091-150X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY., 1960, pages 3457-3461, CHEMICAL SOCIETY,, 1960, pages 3457-3461, CHEMICAL SOCIETY, 196		Database accession no. 6432016 XP002257556 abstract & BLUME, H ET AL: ARZNEIMITTEL FORSCHUNG / DRUG RESEARCH., vol. 31, no. 10, 1981, pages 1731-1735, VERLAG FUER NATURWISSENSCHAFTEN GMBH, AULENDORF., DE	
XP002257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579–582, CONSULTANTS BUREAU, NAW YORK, NY, US ISSN: 0091-150X DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY, 1960, pages 3457–3461, CHEMICAL SOCIETY, LONDON, GB ISSN: 0368-1769 X US 4 670 584 A (FUKUSHIMA KOJI ET AL) 2 June 1987 (1987-06-02) examples S-27; table 2 WO 00 50397 A (TAKAHASHI AKIHIRO ;KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3 claim 1 US 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22)	x 🗸	Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE;	1,8-15
Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY. 1960, pages 3457-3461, CHEMICAL SOCIETY, LONDON, GB ISSN: 0368-1769 X US 4 670 584 A (FUKUSHIMA KOJI ET AL) 2 June 1987 (1987-06-02) examples S-27; table 2 —— WO 00 50397 A (TAKAHASHI AKIHIRO; KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3 claim 1 —— US 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22)		XPO02257557 abstract & TOPUZYAN, V O ET AL: PHARMACEUTICAL CHEMISTRY JOURNAL., vol. 26, no. 7, 1992, pages 579-582, CONSULTANTS BUREAU, NAW YORK, NY, US	
examples S-27; table 2 WO 00 50397 A (TAKAHASHI AKIHIRO ;KATO MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3 claim 1 US 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22)	x ✓	Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2696475 XP002257558 abstract & ACHESON, R M ET AL: JOURNAL OF THE CHEMICAL SOCIETY., 1960, pages 3457-3461, CHEMICAL SOCIETY, LONDON, GB	
MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3 claim 1 US 4 714 713 A (FUKUSHIMA KOJI ET AL) 22 December 1987 (1987-12-22)	X /	2 June 1987 (1987-06-02)	1,2,5,6
22 December 1987 (1987-12-22)	A /	MASAHIKO (JP); YAMADA SHIGEO (JP); ADACHI) 31 August 2000 (2000-08-31) page 14, line 13 -page 15, line 8 table 3	1-18
	A .	22 December 1987 (1987-12-22)	1-7
1			



Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 18 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	k on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

mation on patent family members

P 03/06168

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0168591 ·	A 20-09-2001	AU	5216801 A	24-09-2001
WO 0100331	20 09 2001	BR	0109235 A	17-12-2002
		CA	2401502 A1	20-09-2001
		CN	1418187 T	14-05-2003
		CZ	20023422 A3	15-01-2003
		WO	0168591 A1	20-09-2001
		EP	1265853 A1	18-12-2002
		ΗU	0300188 A2	28-06-2003
		JP	2003527368 T	16-09-2003
•		NO	20024387 A	21-10-2002
		US	2001056100 A1	27-12-2001
US 4670584	A 02-06-1987	JP	1806182 C	26-11-1993
00 1070001	02 00 1507	JP	5018813 B	15-03-1993
	•	JP	59190926 A	29-10-1984
	•	JP	58189121 A	04-11-1983
		ČA	1250090 A1	14-02-1989
		DE	3382112 D1	21-02-1991
		DK	192583 A	31-10-1983
-		EP	0093551 A2	09-11-1983
•		US	4650785 A	17-03-1987
WO 0050397	A 31-08-2000	JP	2000247953 A	12-09-2000
		AU	2691100 A	14-09-2000
		WO	0050397 A1	31-08-2000
US 4714713	A 22-12-1987	JP	62053954 A	09-03-1987
		DE	3666423 D1	23-11-1989
		DK	169403 B1	24-10-1994
•	,	EΡ	0218356 A1	15-04-1987
·		US	4774259 A	27-09-1988